NBSE NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

$8.68
As of 03/04/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
07/15/2019
23,180,024
294,173
$201,202,608
0.00%
SEC Edgar Online
10-Q
10-K
64132K102
US64132K1025
BJ9NDZ8

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
173.60
0.00
-59.42%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy